CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 20 clinical trials at NIH that match your search criteria

Cancer by type/disease: Lung Cancer

Trial and Protocol Number Lung Cancer	Principal Investigator	Referral Contact
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Adults With Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Two or More Prior Treatment Regimens NCI-09-C-0018	Giuseppe Giaccone 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-Small Cell Lung Cancer: An International Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-Line, Platinum-Based Combination Chemotherapy NCI-08-C-0083	Giuseppe Giaccone 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase III Evaluation of Recombinant MAGE-A3 Vaccine as Adjuvant Therapy Following Resection of MAGE-A3-Positive Non-Small Cell Lung Cancer NCI-08-C-0075	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Phase II
Phase II Study of Neoadjuvant Gemcitabine, Cisplatin, and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer NCI-09-C-0107	Giuseppe Giaccone 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Pilot Trial of Pioglitazone in Patients Undergoing Surgical Resection of Non-Small Cell Lung Cancer NCI-08-C-0208	Giuseppe Giaccone 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II, Open-Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients With Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regimen and Failure of Prior Treatment With Erlotinib NCI-08-C-0086	Giuseppe Giaccone 301-496-4916	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase I/II
An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC) NCI-08-C-0166	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I/II Trial of Pemetrexed (Alimta^®) Combined With Sirolimus (Rapamycin, Rapamune^®) in Subjects With Relapsed or Refractory NSCLC Whose Tumors Bear Activation of mTOR NCI-08-C-0078	Phillip A. Dennis 301-496-0929	Hyejeong Root 301-402-0998 roothy@mail.nih.gov
A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer NCI-04-C-0049	John C. Morris 301-402-2912	Nancy Harold 301-435-5612 haroldn@mail.nih.gov
Phase I
Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion in Patients With Malignancies Involving Lungs, Esophagus, or Pleura NCI-05-C-0010	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
No Phase
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer NCI-09-C-0103	Giuseppe Giaccone 301-496-4916	Corrine Keen 301-496-3778 ckeen@mail.nih.gov
Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies NCI-06-C-0014	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors NCI-09-C-0138	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes NCI-09-C-0047	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases NCI-07-C-0230	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Phase I
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers NCI-09-C-0173	Richard Piekarz 301-496-1196	Robin Frye 301-402-5958 fryer@mail.nih.gov
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression NCI-09-C-0168	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Trial of Nelfinavir (Viracept^®) in Adults With Solid Tumors NCI-07-C-0047	Phillip A. Dennis 301-496-0929	Hyejeong Root 301-402-0998 roothy@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors NCI-00-C-0121	John E. Janik 301-402-2913	Debbie Draper 301-435-8525 draperde@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy NCI-09-C-0100	Aradhana Kaushal 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.